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Health-care coverage, especially from health
maintenance organizations (HMOs), often in-
cludes pharmacy benefits. Pharmacy dispensing
records can identify cases of tuberculosis (TB)
unknown to the public health system (1). In this
article, we examine the utility of automated
pharmacy dispensing data in assessing the
quality of management of active TB and patients’
compliance with recommended therapy.
Methods
We used automated pharmacy dispensing
records to characterize therapy in 45 cases of
active TB diagnosed from January 1, 1992, through
June 30, 1996, at Harvard Pilgrim Health Care,
a mixed model HMO in New England. These
were all known cases of TB in a sample of 350,000
HMO members (1,2); all met the Centers for
Disease Control and Prevention’s (CDC) surveil-
lance case definition (3). Cases were drawn from
the 90% of HMO members with pharmacy benefits.
We identified all dispensings of isoniazid,
rifampin, pyrazinamide, ethambutol, streptomycin,
ethionamide, kanamycin, cycloserine, capreomycin,
and para-aminosalicylic acid (PAS). We also
reviewed the full medical records. Empiric
regimens, i.e., those dispensed before susceptibility
results were known, and final treatment
regimens were graded for consistency with
American Thoracic Society (ATS) and CDC
guidelines in effect at the time of diagnosis (4,5).
Two measures of the adequacy of therapy were
calculated. 1) The standard regimen dispensed is
a percentage calculated by comparing the
cumulative dose of each drug dispensed with the
total recommended. Each drug received equal
weight to a maximum of 100% per drug, as noted
in the following formula for a three-drug
regimen: percent standard regimen = ([D1/SR1] +
[D2/SR2] + [D3/SR3]) x (100/3), where Dx is the
cumulative dose dispensed of drug X and SRx is
the recommended total dose. Patients with a
score  >80% were considered to have received an
appropriate amount of antituberculosis medications
(6). 2) The days without medication (identical to
the “MED-OUT” adherence index validated for
other medications) (7), for isoniazid or another
drug required for the entire duration of treatment,
is a percentage calculated by dividing the total
number of days without medication (based on
medication refill intervals and quantities
dispensed) by the number of days between the
first and last dispensing. The last refill does not
influence this calculation. All the preceding
calculations included all medicine dispensed to a
patient, from all pharmacies required to report
dispensing to the HMO to be reimbursed.
Results
Medical records indicated that 27 (60%) of 45
TB cases were treated solely by HMO providers
(Table 1); nearly all remaining patients received
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We used automated pharmacy dispensing data to characterize tuberculosis (TB)
management for 45 health maintenance organization (HMO) members. Pharmacy
records distinguished patients treated in HMOs from those treated elsewhere. For cases
treated in HMOs, they provided useful information about appropriateness of prescribed
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Table 1. Characteristics of tuberculosis cases
Tuberculosis cases treated Tuberculosis cases treated
   in HMO, n = 27 (60%) outside HMO, n = 18 (40%)
Mean age       39      40
Male   16 (59%)   7 (39%)
Foreign born   22 (81%) 15 (83%)
Pulmonary disease, with or without   12 (44%)   9 (50%)
  extrapulmonary involvement
Adequate prescribed regimen by   26 (96%) 17 (94%)
  treating physician
Antituberculosis medications dispensed   26 (96%) 15 (83%)
  through HMO pharmacies
Duration (in days) of antituberculosis 189 (148-291)   1 (0-32)
  medication dispensing by HMO
  (median, interquartile range)
Standard regimen dispensed by HMO   99% (86%-100%) 24% (17%-40%)
  (median, interquartile range)
Figure 1. Pharmacy dispensing profiles of tuberculosis (TB) cases
treated in the health maintenance organization (HMO) and outside
the HMO. Standard regimen (percentage) and duration of
dispensing of antituberculosis medication dispensed for TB cases.
A cutoff value of >70 days of medication dispensed from HMO-
reimbursed pharmacies, as assessed from automated pharmacy
records, differentiated HMO-treated cases from cases at least
partially treated outside the HMO.
their non-HMO care in public
health-funded TB programs.
Thirty-seven (82%) cases re-
ceived empiric regimens through
pharmacies reimbursed by the
HMO. In 34 (92%) instances, the
empiric regimen dispensed was
appropriate; for the remainder,
empiric regimens contained too
few drugs. Twenty-six (96%) of
the 27 solely HMO-treated
cases were prescribed a final
antituberculosis regimen that
was adequate in agents used,
doses prescribed, and duration
of treatment.
In 15 of the 18 cases treated
at least partially outside the
HMO, patients received some
antituberculosis medication from
pharmacies reimbursed by the
HMO. In 14 of these cases,
patients received medications
only once or twice. A cutoff value
of 70 days of drug dispensing
through HMO-reimbursed phar-
macies differentiated HMO-
treated cases from cases treated
in other settings. Among HMO-
treated cases, 26 (96%) of 27
patients received medications for
70 days, compared with 1 (6%) of
18 who were at least partially
treated outside the HMO (Figure
1) (RR = 17, 95% confidence790 790 790 790 790 Emerging Infectious Diseases Vol. 5, No. 6, November–December 1999
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Figure 2. Appropriateness of the amount of antituberculosis
medications dispensed and the timeliness of medication refills.
Percentage of standard regimen dispensed is plotted against
percentage of days without antituberculosis medication for
tuberculosis cases treated in the health maintenance organization.
interval [CI] 3 to 117, p <0.0001) (8). In HMO
cases, median duration of dispensing from HMO
pharmacies was 189 days (interquartile range:
148 days to 291 days) and the median standard
regimen dispensed score was 99% (interquartile
range: 86% to 100%). In cases outside the HMO,
median duration of dispensing through HMO-
reimbursed pharmacies was 1 day (interquartile
range: 0 days to 32 days), and the median
standard regimen dispensed score was 24%
(interquartile range: 17% to 40%). Figure 2
shows the relationship between the appropriate-
ness of the amount of medications dispensed and
the timeliness of medication refills. In 4 (15%) of
26 HMO-treated cases, standard regimen dis-
pensed scores were <80%, and days without
medication scores were >30%. In only one of
these four undertreated cases did the treating
physician document nonadherence. Two other
patients who received 100% of a standard regimen
with unremarkable refill intervals were noted as
noncompliant in physicians’ medical records.
Conclusions
Automated pharmacy data provided useful
information both about physicians’ intended
management of TB and about patients’
adherence to prescribed therapy. The ability to
monitor these aspects of TB care efficiently is
particularly important when care is decentral-
ized or a substantial proportion of patients
receive care from more than one provider. We
were able to determine that in nearly all cases
appropriate initial or empiric regimens were
prescribed, and that in most cases managed by
HMO providers full ATS/CDC-recommended
regimens were dispensed. This approach was
thus more informative and efficient than prior
study methods that assessed prescribed regi-
mens by reviewing patients’ medical records (9).
Many HMOs and other insurers routinely
monitor pharmacy dispensing records for
various reasons. While the initial cost of creating
a routine monitoring report varies, the marginal
cost of running it periodically is usually
negligible. This allows 100%
surveillance of therapy, com-
pared with manual record
review, which is more ex-
pensive even when only a
sample of records is re-
viewed. Additional investi-
gation would determine
whether this method will be
helpful for other infectious
diseases, such as pelvic
inflammatory disease.
In using a pharmacy-
based system to monitor
adherence to therapy, it is
important to identify cases
treated solely within a
delivery system, since auto-
mated pharmacy informa-
tion is reliably complete
only for these persons.
Restricting to patients with
at least 70 days of therapy
accomplishes this, since it
excludes those who receive
empiric regimens within
one health system and then
complete their care at an-
other. Most care delivered
by non-HMO providers was791 791 791 791 791 Vol. 5, No. 6, November–December 1999 Emerging Infectious Diseases
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provided by public health clinics. Potential
physician incentives for transfer of care included
closer monitoring of therapy by experts in TB
treatment, particularly in difficult-to-manage
cases. Patients’ incentives included free medica-
tions provided by the department of public
health. Although all patients described here had
pharmacy benefits, the cost to the patients of
copayments for a standard treatment regimen
would have been $75 to $200.
Monitoring automated pharmacy records of
patients treated for TB was an efficient adjunct
for monitoring adherence but did not entirely
replace providers’ assessments documented in
the medical records. It also provided no
advantage in settings that used directly observed
therapy, which is not routinely used in
Massachusetts.
Pharmacy records may be used to contribute
to management of TB in two ways: in real time, to
identify suboptimal regimens and noncompliant
patients and periodically, to assess overall
appropriateness of care. In real time, one might
monitor the dispensing of antituberculosis
medications for confirmed cases of TB, interven-
ing if necessary with physicians to ensure that
appropriate regimens are used and with patients
to minimize gaps in dispensing. Identifying
noncompliant patients in a regular and timely
manner could allow for interventions (e.g.,
directly observed therapy) to improve adherence
to the treatment regimen. Such oversight could
be coordinated with or overseen by public health
agencies. Coordination between delivery sys-
tems and public health agencies is expected to
become an important element of TB control (10).
Periodic assessment of dispensing records can
also provide a simple, efficient measure of the
overall appropriateness of TB care in a wide
array of settings. These measures would allow
targeting of resources to improve organizations’
management of TB. If these findings are
confirmed in other settings, routine monitoring
of dispensing of antituberculosis medications
may be useful as an adjunct to other methods of
assessing and ensuring appropriate therapy.
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